Ministry of Health and Prevention Chairs Second Meeting of Board of Trustees of the pharmaceutical Sector

Ministry of Health and Prevention Chairs Second Meeting of Board of Trustees of the pharmaceutical Sector
17 June 2017 -
  • Ministry of Health and Prevention Chairs Second Meeting of Board of Trustees of the pharmaceutical Sector
    Ministry of Health and Prevention Chairs Second Meeting of Board of Trustees of the pharmaceutical Sector Ministry of Health and Prevention Chairs Second Meeting of Board of Trustees of the pharmaceutical Sector

H.E. Dr. Amin Hussein Al Amiri, Assistant Undersecretary for Public Health Policy and Licensing of the Ministry of Health and Avoidance and chairman of the pharmaceutical board of trustees in UAE, chaired the recently held second meeting of the Board of Trustees of the pharmaceutical market. Execs from local and worldwide pharmaceutical company attended the meeting, in addition to local medicine suppliers, executives from personal drug store chains, Ministry and local health authority's officials.

H.E. Dr. Al Amiri stated that the Board of Trustees was formed in pursuant of Pastoral mandate No. 158 of 2017. Adhering to the instructions of the Minister of Health and Avoidance, the Board members were very carefully selected to make certain that stakeholders in the pharmaceutical field would be fairly represented.

Code of ethical pharmaceutical promotional and commercial practices
Inning accordance with the Assistant Undersecretary, the participants got to numerous choices on pushing problems during the meeting, including the standards for the pharmaceutical advertising and industrial methods established to ensure that prescription and dispensing of medicines are based upon the functions of each item and on the individuals need. The overview suggests the appropriate percent of rewards in the nation.

Spotlight on locally produced medicines
H.E. Dr. Al Amiri likewise evaluated the Board's obligations, including the establishment of a device for examination, teamwork, and coordination in important matters with connection to the pharmaceutical market, consisting of policies, growth of executive strategies controling the distribution of medications to protect public health, along with the analysis of the characteristics of this market and its difficulties and variables impacting the local pharmaceutical market. The executive strategies are within the legal structure controling medication distribution and advertising control in between parties concerned in this market. The control will certainly make certain sufficient supply of pharmaceutical products according to national requirements.

Spotlight on locally created medications
Furthermore, H.E. Dr. Al Amiri said the Board is additionally tasked to create efficient devices devoted to facilitating the circulation of pharmaceutical products in the country, along with encouraging innovation and imagination in the market to guarantee the local market's continuous growth and development. The Board participants are additionally mandated to research numerous financial investment networks within the sector and prolong support to locally produced innovative medications to raise the country's pharmaceutical industry's global competition. He also highlighted the new treatments that have actually been taken on to help accelerate the registration procedure, specifically the innovative medications authorized by the international bodies of medicine, consisting of the approval of the files of medications before its authorization in the country of origin - making the UAE the second nation in the world to screen, adopt and approve innovative drugs.

Focusing on the production of medicines for chronic diseases and preventing duplication of drug manufacturing
Lastly H.E. pointed that the Board's objectives consist of laying the foundation for a healthy and balanced competition in the market, avoid duplication in drug manufacturing, motivate expertise, and advertise diversity in the pharmaceutical industry. The Board is concentrating too on the production of drugs used to deal with persistent diseases, consisting of diabetes mellitus, obesity, hypertension, and heart diseases, that call for chronic treatment programs, according to the nation's objective to assure medicine safety and security in the local market. Also the board reviewed was acceptance of some local manufacturing facilities to generate medicines that are not provided by the global suppliers, and these will certainly be distributed in the UAE and the Middle East and North Africa (MENA) region.